Insider Selling: Incyte Co. (INCY) EVP Sells 5,000 Shares of Stock
Incyte Co. (NASDAQ:INCY) EVP Vijay K. Iyengar sold 5,000 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $97.26, for a total transaction of $486,300.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Incyte Co. (NASDAQ:INCY) traded up $0.09 during mid-day trading on Wednesday, hitting $100.98. 1,458,486 shares of the company were exchanged, compared to its average volume of 1,643,950. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.82 and a quick ratio of 4.81. Incyte Co. has a 12-month low of $92.91 and a 12-month high of $153.15. The stock has a market capitalization of $21,310.00, a price-to-earnings ratio of -126.23 and a beta of 0.74.
Incyte (NASDAQ:INCY) last released its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.11. Incyte had a negative net margin of 10.90% and a negative return on equity of 12.91%. The firm had revenue of $381.50 million for the quarter, compared to analyst estimates of $360.34 million. During the same period in the prior year, the firm earned $0.19 earnings per share. The business’s quarterly revenue was up 41.6% compared to the same quarter last year. sell-side analysts forecast that Incyte Co. will post -1.33 earnings per share for the current fiscal year.
A number of research analysts have commented on INCY shares. Raymond James Financial raised shares of Incyte from a “market perform” rating to an “outperform” rating and set a $159.00 target price on the stock in a research report on Monday, September 11th. Deutsche Bank started coverage on shares of Incyte in a research report on Tuesday, December 12th. They issued a “hold” rating and a $106.00 target price on the stock. Oppenheimer reaffirmed a “hold” rating and issued a $135.00 target price on shares of Incyte in a research report on Sunday, September 10th. Argus reaffirmed a “buy” rating and issued a $150.00 target price on shares of Incyte in a research report on Wednesday, September 13th. Finally, BMO Capital Markets decreased their target price on shares of Incyte from $163.00 to $162.00 and set an “outperform” rating on the stock in a research report on Thursday, October 26th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. Incyte has a consensus rating of “Buy” and a consensus price target of $143.11.
ILLEGAL ACTIVITY WARNING: “Insider Selling: Incyte Co. (INCY) EVP Sells 5,000 Shares of Stock” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/03/insider-selling-incyte-co-incy-evp-sells-5000-shares-of-stock.html.
Incyte Company Profile
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.